Chemotherapy plus two new drugs before surgery for mid-rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy plus two newer medicines (suvemcitug and enlonstobart) before surgery for middle rectal cancer. The goal is to shrink the tumor and avoid radiation therapy, which may spare some side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of rectal cancer called adenocarcinoma (the most common type) that is in the middle part of the rectum.
- Your rectal cancer must be locally advanced (has grown deep into the rectal wall or spread to nearby lymph nodes) but has not spread to other organs.
- You must be generally healthy and able to care for yourself (ECOG score 0 or 1).
- You must not have had prior chemotherapy, radiation to the pelvis, or immunotherapy for this cancer.
- You must have adequate organ function (kidney, liver, blood counts) as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This study tests a new combination of treatment before surgery for high-risk rectal cancer. It combines a shorter course of radiation with chemotherapy and immunotherapy (which helps your immune system fight cancer) to see if it shrinks the tumor and improves outcomes.
This trial tests whether giving chemotherapy and an immunotherapy drug before surgery can help shrink rectal cancer tumors and improve outcomes. It is for patients whose tumors are not caused by a specific genetic mismatch repair problem.
This trial tests whether combining chemotherapy (mFOLFOX6) and a short course of radiation before surgery improves outcomes for people with resectable rectal cancer. The goal is to shrink and control the cancer early and then remove it with curative surgery.
This trial tests a combination of chemotherapy and radiation therapy before surgery for people with mid or low rectal cancer that hasn't spread. The goal is to see if this approach works better than current treatments.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.